4D Molecular Therapeutics, Inc. (FDMT)

Market Cap	173.63M
Revenue (ttm)	37,000
Net Income (ttm)	-160.87M
Shares Out	46.30M
EPS (ttm)	-2.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	642,823
Open	3.740
Previous Close	3.790
Day's Range	3.674 - 3.845
52-Week Range	3.660 - 36.250
Beta	2.82
Analysts	Buy
Price Target	35.00 (+833.33%)
Earnings Date	May 8, 2025

About FDMT

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macul...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 147
• Stock Exchange: NASDAQ
• Ticker Symbol: FDMT

Financial Performance

In 2024, 4D Molecular Therapeutics's revenue was $37,000, a decrease of -99.82% compared to the previous year's $20.72 million. Losses were -$160.87 million, 59.5% more than in 2023.

Analyst Forecast

According to 10 analysts, the average rating for FDMT stock is "Buy." The 12-month stock price forecast is $35.0, which is an increase of 833.33% from the latest price.

Price Target

$35.0

(833.33% upside)

Analyst Consensus: Buy